Frankfurt - Delayed Quote EUR

Cytophage Technologies Ltd. (70G.F)

0.1390
-0.0220
(-13.66%)
At close: May 16 at 8:02:18 AM GMT+2
Loading Chart for 70G.F
  • Previous Close 0.1610
  • Open 0.1390
  • Bid --
  • Ask --
  • Day's Range 0.1390 - 0.1390
  • 52 Week Range 0.0290 - 0.2390
  • Volume 2,500
  • Avg. Volume 161
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Winnipeg, Canada.

cytophage.com

--

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 70G.F

View More

Performance Overview: 70G.F

Trailing total returns as of 5/17/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

70G.F
24.86%
MSCI WORLD (^990100-USD-STRD)
4.19%

1-Year Return

70G.F
14.98%
MSCI WORLD (^990100-USD-STRD)
11.25%

3-Year Return

70G.F
14.98%
MSCI WORLD (^990100-USD-STRD)
40.65%

5-Year Return

70G.F
14.98%
MSCI WORLD (^990100-USD-STRD)
0.00%

Compare To: 70G.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 70G.F

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.91M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.36M

  • Total Debt/Equity (mrq)

    38.06%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 70G.F

View More

Company Insights: 70G.F

Research Reports: 70G.F

View More